Theranica brings first-in-class, drug-free migraine care to the forefront at CNS 2025 with product theater and new real-world evidence. News provided by. Oct 08, 2025, 14:48 ET With a dedicated product theater and new real-world evidence posters, Theranica will spotlight how the Nerivio(R) REN wearable is reshaping pediatric migraine care - offering families a proven, drug-free alternative to migraine treatment BRIDGEWATER, N.J. and NETANYA, Israel, Oct. 8, 2025 /PRNewswire/ - Theranica, a pioneer in drug-free neuromodulation treatments for idiopathic pain conditions, today announced its participation at the 2025 Child Neurology Society (CNS) Annual Meeting, held in Charlotte, N.C. The company will present two new real-world evidence (RWE) posters and host a dedicated product theater session, highlighting the clinical impact of the FDA-cleared Nerivio(R) Remote Electrical Neuromodulation (REN) wearable indicated for both acute and preventive treatment of migraine in people aged 8 and older. The new data add to the growing body of evidence demonstrating the long-term effectiveness and safety of the Nerivio REN wearable as a non-pharmacological option for patients: * RWE10: Timing of treatment - In one of the largest prospective real-world studies of migraine to date (55,000 patients, including nearly 9,000 children and adolescents), data revealed that REN treatments which were initiated within one hour of migraine onset were nearly twice as likely to achieve pain relief, pain freedom and freedom from associated symptoms compared to attacks with delayed treatment (p<0.001). These findings emphasize the clinical importance of timely intervention with the REN wearable. * RWE08: Three-year outcomes - A longitudinal study showed no tachyphylaxis (treatment fatigue) and consistent efficacy over three years of monthly treatment with the Nerivio REN wearable. Patients used the device an average of 8.4 times per month, achieving sustained pain relief (~74%) and functional disability relief (~70%). Outcomes remained stable over time with minimal device-related adverse events, underscoring tolerability and long-term safety. Alongside the poster presentations, Theranica will host a product theater showcasing the Nerivio REN wearable's unique role in pediatric neurology. Clinicians will gain insights into its use for both acute and preventive treatment in the pediatric population, without the risks associated with drugs, needles or invasive procedures. "We are excited to engage with the pediatric neurology community at this year's CNS Annual Meeting," said Alit Stark-Inbar, VP of Medical Information and Research at Theranica. "Through our product theater and new real-world evidence studies, we look forward to highlighting the clinical value of the Nerivio(R) REN wearable as a safe, drug-free migraine treatment option for children and adolescents. Our participation at CNS underscores Theranica's commitment to advancing innovative, family-friendly solutions that meet the unique needs of young patients living with migraine." The new findings further demonstrate the long-term safety, efficacy and clinical value of the Nerivio REN wearable for people living with migraine. By sharing this evidence with the pediatric neurology community at CNS 2025, Theranica continues to highlight its commitment to expanding access to drug-free, clinically proven interventions that empower patients to better manage migraine symptoms. About Nerivio The Nerivio(R) REN wearable is an acute and preventive (dual-use) prescription migraine treatment that works without drugs, needles, or invasive procedures. FDA-cleared for patients 8 and above, it uses gentle electrical pulses on the arm to activate the brain's natural pain regulation system, relieving migraine symptoms during an attack, and reducing the frequency and burden of future episodes when used preventively. Controlled by a smartphone app, the Nerivio REN wearable offers a safe, effective, and easy-to-use way to manage migraine - without the risk of systemic side effects or drug interactions. About Theranica Theranica is a neuromodulation therapeutics company pioneering drug-free treatments for idiopathic pain conditions. Its FDA-cleared flagship product, Nerivio(R), is the first-and-only prescribed REN wearable for both acute and preventive migraine care. Used in more than one million treatments across the U.S., Nerivio provides a much-needed option for migraine patient populations with unique qualities, including children, veterans, individuals managing comorbidities, and women of childbearing age. Dedicated to modernizing pain management without drugs or needles, Theranica continues to develop cutting-edge neuromodulation therapies that reshape the way pain is treated. Theranica Contact: Ronen Jashek [email protected] +972-72-390-9750 SOURCE Theranica

The Nerivio® REN wearable is redefining pediatric migraine care as the only migraine-specific preventive therapy for children under the age of 12.BRIDGEWATER, N.J. and NETANYA, Israel, Dec. 10, 2024 /PRNewswire/ -- Theranica, a prescribed neuromodulation therapeutics company, today announced significant milestones in 2024, including a recently released study highlighting barriers and preferences when treating migraine at school. Other achievements this year include an expanded age indication from the FDA, clearing the treatment for use in patients aged eight and older; the appointment of a new chief medical officer; and improved access and affordability with insurance coverage reaching 30 million people

Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine.BRIDGEWATER, N.J. and NETANYA, Israel, July 25, 2024 /PRNewswire/ -- Theranica , a neuromodulation therapeutics company, today announced that Annals of the Child Neurology Society has published results from a prospective real-world evidence study evaluating the safety and efficacy of remote electrical neuromodulation (REN) as a treatment for migraine in children ages 6 to 11. The Nerivio ® REN wearable is the first FDA-cleared, non-drug, easy-to-use treatment for both acute migraine attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older. The treatment is currently under FDA review to possibly expand the indication to eight years of age and older."This study has shown that REN is a valuable tool for migraine treatment even in younger children," said Dr. Trevor Gerson, MD, Headache Specialist, Children's Mercy Kansas City. Post this The Nerivio REN wearable is the first non-drug, non-disruptive migraine treatment that can be used anywhere, allowing adolescents to participate in activities and school while actively managing their migraine.This recently published clinical study, involving 293 children aged 6 to 11, has shown promising results regarding the safety and effectiveness of the Nerivio REN wearable device as a non-pharmacological treatment for migraine.At two hours post-treatment, 72.2% of patients reported pain relief, 36.0% achieved pain freedom, 83.3% experienced functional disability relief, and 38.9% attained functional disability freedom